There is worry that the recent decline in copper and China's economic woes might be the start of a wider correction.» Read More
*Boeing finds cracks in wings of Dreamliners in production. *Facebook shares hit another record after UBS raises target. NEW YORK, March 10- U.S. stocks dipped on Monday, weighed down by soft data out of China and Boeing's latest production setback.
*Facebook shares hit another record after UBS raises target. NEW YORK, March 10- U.S. stocks fell on Monday weighed by soft data out of China, lingering concerns over Russia's claim over part of Ukraine and Boeing's latest production setback.
Soliris, the company's sole product on the market, is approved in the United States, the European Union and Japan for the two conditions. The drugmaker raised its full-year adjusted earnings forecast to $4.37- $4.47 per share from its previous estimate of $3.70- $3.80.
March 10- Alexion Pharmaceuticals Inc revised its profit and sales outlook for the year after the French government agreed to raise reimbursement payments for the company's lead drug, Soliris. The drugmaker raised its full-year adjusted earnings forecast to $4.37- $4.47 per share from its previous estimate of $3.70- $3.80 per share.
*Hasbro rallies after results, upbeat comments. NEW YORK, Feb 10- U.S. stocks ended with modest gains on Monday as investors digested recent market gains and looked ahead to new Federal Reserve Chair Janet Yellen's first testimony before lawmakers.
Jan 30- Shares of Alexion Pharmaceuticals Inc soared 27 percent to a life-high after the company forecast $2 billion in sales for its blood disorder drug this year ahead of analysts' average estimate.
Some of Thursday's midday movers:
Jan 30- Alexion Pharmaceuticals Inc said it expected revenue from its blood disorder drug, Soliris, to hit the $2 billion mark in 2014, sending its shares up 27 percent to a life-high. Sales are expected to rise to between $2 billion to $2.02 billion in 2014 from $1.55 billion in 2013..
It’s time for the Lightning Round. Cramer makes the call on viewer favorites.
NEW YORK, Sept 19- Roche Holding AG is not raising financing to acquire BioMarin Pharmaceuticals, a Roche spokesman told Reuters Thursday, contradicting a report that had lifted BioMarin shares almost 10 percent in pre-market trading.
“As terrific as Google’s percent gain has been since its IPO 9 years ago, it’s been dwarfed by these stocks,” Cramer said.
For investors still uncertain about the euro zone's prospects, analysts say there is a safer way to play its nascent recovery: Buy shares of U.S. companies that do a lot of business there.
Biotech stocks are some of the best-performing S&P stocks this month. Chris Raymond, senior biotech analyst at Robert W. Baird, shares his top picks.
Pharmaceutical and biotech stocks have outperformed markets this year, and with J&J's second-quarter earnings beat, investors may hope earnings will push stocks even higher.
Stocks finished modestly higher in lackluster trading Monday, with the Dow and S&P 500 closing at new highs for the third-straight session, as investors digested a handful of mixed economic data and ahead this week's slew of earnings reports.
U.S. stock index futures shaved some gains Monday, as investors digested a weaker-than-expected retail sales report against China's annual GDP data that met expectations.
Some of the names on the move ahead of the open.
Looking for a small stock with big return potential? Jim Cramer thinks you should consider this.
Had you picked stocks thoughtfully and carefully since Mad Money began, you would have beaten the S&P by 3000%!
CNBC’s Analytics team looked at the stocks that have average consensus estimates farthest above their current stock prices. Here's what they found.